Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
The Effect of Metformin on Fecundability in an ART(Assisted Reproductive Technology) Setting - the Correlation to Uterine Flows
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- The Baruch Padeh Medical Center, Poriya
- Target Recruit Count
- 100
- Registration Number
- NCT02848950
Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Registration Number
- NCT02848508
- Locations
- 🇫🇷
CHU Amiens, Amiens, France
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 22
- Registration Number
- NCT02846233
- Locations
- 🇺🇸
UCSF Fresno, Fresno, California, United States
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 892
- Registration Number
- NCT02836704
Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 290
- Registration Number
- NCT02831361
DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT02815397
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
The Drug-drug Interaction of SP2086 and Metformin
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02813863
Effects of Metformin Treatment on Myocardial Efficiency in Patients With Heart Failure
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT02810132
- Locations
- 🇩🇰
Aarhus University Hospital, Department of Cardiology, Palle Juul-Jensens Boulevard 99, Aarhus N, Denmark
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 23
- Registration Number
- NCT02803918
- Locations
- 🇺🇸
Investigational Site Number 840006, New Orleans, Louisiana, United States
🇹🇷Investigational Site Number 792002, Ankara, Turkey
🇺🇸Investigational Site Number 840002, Baton Rouge, Louisiana, United States
Metformin for Prevention Gestational Diabetes in Pregnant Women With Polycystic Ovarian Syndrome
- Conditions
- Diabetes, GestationalPolycystic Ovary Syndrome
- Interventions
- Drug: placebo (folic acid )Drug: metformin
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 80
- Registration Number
- NCT02802215
- Locations
- 🇪🇬
Ain Shams maternity hospital, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.